Synerk
Founded in Boston, USA, with the support of the world's top venture capital fund, the core team is a leading international biotechnology company with complete successful experience in the research and development of new micronucleic acid drugs and clinical proprietary medicines. The company's product pipeline not only covers a number of major diseases and a variety of rare disease clinical drug products, but also includes a variety of global first-in-class products.
Synerk
Founded in Boston, USA, with the support of the world's top venture capital fund, the core team is a leading international biotechnology company with complete successful experience in the research and development of new micronucleic acid drugs and clinical proprietary medicines. The company's product pipeline not only covers a number of major diseases and a variety of rare disease clinical drug products, but also includes a variety of global first-in-class products.
Synerk
Founded in Boston, USA, with the support of the world's top venture capital fund, the core team is a leading international biotechnology company with complete successful experience in the research and development of new micronucleic acid drugs and clinical proprietary medicines. The company's product pipeline not only covers a number of major diseases and a variety of rare disease clinical drug products, but also includes a variety of global first-in-class products.
SynerK was established to transform the science of Nobel laureates into therapies that change the lives of patients. We use scientifically and / or clinically proven techniques to alter mRNA expression to regulate protein levels and / or function. Our mission is to realize the full potential of RNA targeted therapy and to meet the unmet medical needs of patients.
Research and Development
